Supplementary Table 5. *Post-hoc* analyses comparing the end-of-treatment virological, biochemical, and histologic parameters according to treatment allocation in the TORCH-B trial

Outcomes at the end	TDF in the TORCH-B trial (n=62)	Placebo in the TORCH-B trial (n=61)	*P*-value
HBV DNA, log IU/mL	ND (ND, ND)	ND (ND, ND)	0.63
Viral remission, n (%)	51 (82.3)	51 (83.6)	1.0
ALT, U/L	31 (25–42)	34 (25–53)	0.45
ALT normalization, n (%)	47 (75.8)	40 (65.6)	0.24
Fibrosis Stage <3, n (%)	58 (93.5)	53 (86.9)	0.24
Inflammation score <4, n (%)	55 (88.7)	55 (90.2)	1.0

Viral remission was defined as undetectable HBV in serum (lower detection limit: 20 IU/mL) and ALT normalization defined by the serum level of ALT <40 U/L. Between-group differences were assessed using the Wilcoxon rank-sum test for continuous variables and Fisher's exact test for categorical variables.

 https://doi.org/10.3350/cmh.2024.0640